{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T09:58:30Z","timestamp":1772359110671,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.remnie.2025.500205","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:11:13Z","timestamp":1756743073000},"page":"500205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive value of metastatic distribution patterns on [68Ga]Ga-PSMA PET\/CT for [177Lu]Lu-PSMA therapy"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7563-3484","authenticated-orcid":false,"given":"Y.B.","family":"Cayirli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Elboga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remnie.2025.500205_bib0005","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231157632","article-title":"Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials","volume":"15","author":"Jang","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.remnie.2025.500205_bib0010","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00259-018-4042-z","article-title":"68Ga-PSMA-11 PET\/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer","volume":"45","author":"Schmidkonz","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2025.500205_bib0015","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.remnie.2025.500205_bib0020","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.remnie.2025.500205_bib0025","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s12149-022-01739-3","article-title":"The role of Ga68 PSMA PET\/CT imaging in Lu177 PSMA treatment planning in metastatic castration-resistant prostate cancer","volume":"36","author":"Erdogan","year":"2022","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.remnie.2025.500205_bib0030","first-page":"1651","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study [published correction appears in J Nucl Med. 2023 Sep;64(9):1503]","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500205_bib0035","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","article-title":"Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria","volume":"49","author":"Gafita","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2025.500205_bib0040","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT [published correction appears in J Nucl Med. 2018 Jun;59(6):992]","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500205_bib0045","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/s41596-021-00662-7","article-title":"Synthesis of 68Ga-radiopharmaceuticals using both generator-derived and cyclotron-produced 68Ga as exemplified by [68Ga]Ga-PSMA-11 for prostate cancer PET imaging","volume":"17","author":"Rodnick","year":"2022","journal-title":"Nat Protoc"},{"key":"10.1016\/j.remnie.2025.500205_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105682","article-title":"A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT","volume":"9","author":"Hirata","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.remnie.2025.500205_bib0055","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2967\/jnumed.118.224055","article-title":"qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using 68Ga-PSMA11 PET\/CT","volume":"60","author":"Gafita","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500205_bib0060","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s12149-019-01342-z","article-title":"Evaluation of whole-body tumor burden with 68Ga-PSMA PET\/CT in the biochemical recurrence of prostate cancer","volume":"33","author":"Brito","year":"2019","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.remnie.2025.500205_bib0065","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13550-019-0572-z","article-title":"Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET\/CT: a bi-centric analysis","volume":"9","author":"Gafita","year":"2019","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.remnie.2025.500205_bib0070","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1007\/s00261-020-02745-7","article-title":"Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of 68Ga-PSMA-11 PET\/CT in newly diagnosed prostate cancer","volume":"45","author":"Zou","year":"2020","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.remnie.2025.500205_bib0075","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1555712","article-title":"Preparation of 177Lu-PSMA-617 in hospital radiopharmacy: convenient formulation of a clinical dose using a single-vial freeze-dried PSMA-617 kit developed in-house","volume":"2021","author":"Guleria","year":"2021","journal-title":"Biomed Res Int"},{"issue":"10276","key":"10.1016\/j.remnie.2025.500205_bib0080","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.remnie.2025.500205_bib0085","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.remnie.2025.500205_bib0090","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.879089","article-title":"Correlation between quantitative PSMA PET parameters and clinical risk factors in non-metastatic primary prostate cancer patients","volume":"12","author":"Zschaeck","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.remnie.2025.500205_bib0095","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00259-020-04981-x","article-title":"PSMA whole-body tumor burden in primary staging and biochemical recurrence of prostate cancer","volume":"48","author":"Santos","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2025.500205_bib0100","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s12149-019-01387-0","article-title":"68Ga-PSMA-11 PET\/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients","volume":"33","author":"Schmidkonz","year":"2019","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.remnie.2025.500205_bib0105","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2967\/jnumed.121.261906","article-title":"Tumor sink effect in 68Ga-PSMA-11 PET: myth or reality?","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500205_bib0110","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.remnie.2025.500205_bib0115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating <\u2212\u2212 \u2212\u2212>177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Heck","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500205_bib0120","doi-asserted-by":"crossref","first-page":"103108","DOI":"10.18632\/oncotarget.21600","article-title":"Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy","volume":"8","author":"Ahmadzadehfar","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.remnie.2025.500205_bib0125","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2967\/jnumed.116.178228","article-title":"Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617","volume":"58","author":"Ferdinandus","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500205_bib0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/RLU.0000000000002833","article-title":"Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"45","author":"Yadav","year":"2020","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.remnie.2025.500205_bib0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00259-017-3848-4","article-title":"PSMA targeted radioligand therapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and\/or enzalutamide. A retrospective analysis of overall survival","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2025.500205_bib0140","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3390\/cancers12051078","article-title":"Clinical variables associated with PSA response to lutetium-177-PSMA ([177Lu]-PSMA-617) radionuclide treatment in men with metastatic castration-resistant prostate cancer","volume":"12","author":"Gadot","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.remnie.2025.500205_bib0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clgc.2018.09.014","article-title":"Results of a prospective phase 2 pilot trial of 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression","volume":"17","author":"Emmett","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.remnie.2025.500205_bib0150","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.18632\/oncotarget.26789","article-title":"177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer","volume":"10","author":"von Eyben","year":"2019","journal-title":"Oncotarget"}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808925001223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808925001223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T09:23:08Z","timestamp":1772356988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808925001223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2253808925001223"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2025.500205","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive value of metastatic distribution patterns on [68Ga]Ga-PSMA PET\/CT for [177Lu]Lu-PSMA therapy","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2025.500205","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2025.500205","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500205"}}